Conceptus Inc: (NASD: CPTS)
$30.98
0.06 (0.19%)
Volume 387,138
May 21 04:00 PM ET
Zacks Rank: 1-Strong Buy 
| #1 |
Overview Quote
Stock Activity
| Day Low - High | 30.93 - 30.98 |
| 52wk Low - High | 15.81 - 31.10 |
| Previous Close | 30.92 |
| Avg. Volume | 1,902,887 |
| Industry | MED PRODUCTS |
| Market Cap | 1.01 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.75 |
| PE (Forward) | 118.35 |
| Current Year Est. | 0.26 |
| Quarterly Earnings ESP |
-16.67% |
Premium research
Zacks Rank
|
 1 |
Zacks Recommendation
|
Outperform |
Zacks Industry Rank
|
179 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 118.35 |
| PEG Ratio | 5.92 |
| Current Year Est. | 0.26 |
| Current Quarter Estimate | 0.06 |
| Most Accurate Estimate | 0.05 |
| Earnings ESP |
-16.67% |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | 0.29 |
| Expected Earnings Growth | 20.00% |
Company Description
Conceptus, Inc. designs and develops minimally invasive devices for reproductive medical applications. Conceptus' focus is to develop its STOP non-surgical permanent contraception device for women. STOP is designed to be a less-invasive, safer, and less costly alternative to surgical sterilization, more commonly known as tubal ligation. The STOP device is designed to achieve contraception by elliciting a tissue response which occludes the fallopian tubes.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.06 | 0.07 | 0.26 | 0.41 |
| Number of Estimates | 7 | 7 | 8 | 6 |
| Low Estimate | 0.04 | 0.05 | 0.19 | 0.28 |
| High Estimate | 0.07 | 0.08 | 0.32 | NA |
| Year Ago EPS | 0.00 | 0.07 | 0.16 | 0.26 |
| EPS Growth | NA | -4.08% | 63.28% | 55.02% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.05 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.69 | |
|
| ABAXIS INC | ABAX | 44.67 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
| BIO-RAD LABS -A | BIO | 116.41 | |
|
| BIOLIFE SOL INC | BLFS | 0.41 | |
|
| BOSTON SCIENTIF | BSX | 9.25 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
THOR Downgraded to Underperform
May 21, 2013
FDA Nod for COV's Advanced Nellcor
May 21, 2013
Yet Another Acquisition for Bayer
May 21, 2013
FDA Nod for Thoratec Controller
May 20, 2013
PKI Downgraded to Underperform
May 20, 2013
CE Mark for STJ's ILUMIEN OPTIS
May 17, 2013
Stryker Reiterated at Neutral
May 17, 2013
Alleged Patent Infringement by BSX
May 17, 2013
Financials
| EPS TTM | 0.29 |
| Sales | 141 |
| Net Income | 10 |
| Price/Earnings | 106.62 |
| Price/Book | 5.66 |
| Price/Cash Flow | 57.47 |
| Price/Sales | 6.90 |
News
A Strategic Healthcare Deal With an Expensive Price Tag - TheMotleyFool
May 8, 2013
A Peek Into The Market Before The Trading Starts - Benzinga
Apr 29, 2013
Bayer HealthCare to Acquire Conceptus for $31/Share - Benzinga
Apr 29, 2013
Bayer Shells Out $1.1B to Buy Conceptus - FOXBusiness.com
Apr 29, 2013
Benzinga`s Top Pre-Market Gainers - Benzinga
Apr 29, 2013
Dow, S&P 500 Approach Highs; Health Care Names Shine Again - Investors Business Daily
Apr 29, 2013
Market Wrap for Monday, April 29: Stocks Start Week With a Rally - Benzinga
Apr 29, 2013
Mid-Afternoon Market Update: Nam Tai Plummets as SINA Rises - Benzinga
Apr 29, 2013
Broker Recommendations
| Current ABR | 2.67 |
| ABR (Last Week) | 2.67 |
| # of recs in ABR | 9 |
| Average Target Price | 26.20 |
| Industry Rank by ABR | 179 out of 265 |
| Rank in Industry | 1 out of 72 |
